Terrie Curran's most recent trade in Arcutis Biotherapeutics Inc was a trade of 20,568 Stock Option (right to buy) done . Disclosure was reported to the exchange on June 12, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Arcutis Biotherapeutics Inc | Terrie Curran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 20,568 | 20,568 | - | - | Stock Option (right to buy) | |
| Arcutis Biotherapeutics Inc | Terrie Curran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 7,609 | 17,748 (0%) | 0% | 0 | Common Stock | |
| Phathom Pharmaceuticals Inc | Terrie Curran | Director, President and Chief Executive | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2025 | 342,500 | 342,500 | - | - | Stock Option (Right to Buy) | |
| Phathom Pharmaceuticals Inc | Terrie Curran | Director, President and Chief Executive | Sale of securities on an exchange or to another person at price $ 6.59 per share. | 21 Jan 2025 | 19,109 | 360,465 (1%) | 0% | 6.6 | 125,884 | Common Stock |
| Arcutis Biotherapeutics Inc | Terrie Curran | Director | Sale of securities on an exchange or to another person at price $ 10.85 per share. | 11 Nov 2024 | 8,687 | 10,139 (0%) | 0% | 10.8 | 94,238 | Common Stock |
| Phathom Pharmaceuticals Inc | Terrie Curran | Director, President and Chief Executive | 15 Jul 2024 | 33,848 | 377,734 (1%) | 0% | 11.7 | 396,699 | Common Stock | |
| Arcutis Biotherapeutics Inc | Terrie Curran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 27,052 | 27,052 | - | - | Stock Option (right to buy) | |
| Arcutis Biotherapeutics Inc | Terrie Curran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 10,139 | 18,826 (0%) | 0% | 0 | Common Stock | |
| Phathom Pharmaceuticals Inc | Terrie Curran | Director, President and Chief Executive | 22 Mar 2024 | 16,851 | 410,784 (1%) | 0% | 9.1 | 153,513 | Common Stock | |
| Phathom Pharmaceuticals Inc | Terrie Curran | Director, President and Chief Executive | 18 Jan 2024 | 475,000 | 475,000 | - | - | Stock Option (Right to Buy) | ||
| Phathom Pharmaceuticals Inc | Terrie Curran | Director, President and Chief Executive | 14 Jul 2023 | 225,000 | 0 | - | - | Stock Option | ||
| Phathom Pharmaceuticals Inc | Terrie Curran | Director, President and Chief Executive | 14 Jul 2023 | 200,000 | 389,671 (1%) | 0% | - | Common Stock | ||
| Phathom Pharmaceuticals Inc | Terrie Curran | Director, President and Chief Executive | 14 Jul 2023 | 175,000 | 0 | - | - | Stock Option | ||
| Arcutis Biotherapeutics Inc | Terrie Curran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2023 | 12,220 | 12,220 | - | - | Stock Option (right to buy) | |
| Arcutis Biotherapeutics Inc | Terrie Curran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2023 | 4,375 | 8,687 (0%) | 0% | 0 | Common Stock | |
| Phathom Pharmaceuticals Inc | Terrie Curran | Director, President and Chief Executive | 06 Apr 2023 | 12,919 | 188,290 (0%) | 0% | 7.8 | 101,025 | Common Stock | |
| Phathom Pharmaceuticals Inc | Terrie Curran | Director, President and Chief Executive | 01 Mar 2023 | 1,436 | 175,371 (0%) | 0% | 8.5 | 12,265 | Common Stock | |
| Phathom Pharmaceuticals Inc | Terrie Curran | Director, President and Chief Executive | 19 Jan 2023 | 162,500 | 162,500 | - | - | Stock Option (Right to Buy) | ||
| Phathom Pharmaceuticals Inc | Terrie Curran | Director, President and Chief Executive | 19 Jan 2023 | 97,500 | 182,628 (0%) | 0% | 0 | Common Stock | ||
| Phathom Pharmaceuticals Inc | Terrie Curran | Director, President and Chief Executive | 19 Jan 2023 | 5,821 | 176,807 (0%) | 0% | 8.2 | 47,729 | Common Stock | |
| Phathom Pharmaceuticals Inc | Terrie Curran | Director, President and Chief Executive | 21 Nov 2022 | 1,526 | 83,720 (0%) | 0% | 9.6 | 14,650 | Common Stock | |
| Phathom Pharmaceuticals Inc | Terrie Curran | Director, President and Chief Executive | 01 Sep 2022 | 7,500 | 85,246 (0%) | 0% | 0 | Common Stock | ||
| Arcutis Biotherapeutics Inc | Terrie Curran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 11,796 | 11,796 | - | - | Stock Option (Right to Buy) | |
| Arcutis Biotherapeutics Inc | Terrie Curran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 4,312 | 4,312 (0%) | 0% | 0 | Common Stock | |
| Phathom Pharmaceuticals Inc | Terrie Curran | Director, President and Chief Executive | 19 May 2022 | 12,000 | 76,595 (0%) | 0% | 0 | Common Stock | ||
| Phathom Pharmaceuticals Inc | Terrie Curran | Director, President and Chief Executive | 13 May 2022 | 20,500 | 64,595 (0%) | 0% | 7.4 | 151,835 | Common Stock | |
| Arcutis Biotherapeutics Inc | Terrie Curran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2021 | 13,391 | 13,391 | - | - | Stock Option (Right to Buy) | |
| Phathom Pharmaceuticals Inc | Terrie Curran | Director, President and Chief Executive | 22 Mar 2021 | 11,513 | 11,513 (0%) | 0% | 6.9 | 80,015 | Common Stock | |
| Phathom Pharmaceuticals Inc | Terrie Curran | Director, President and Chief Executive | 22 Mar 2021 | 11,513 | 855,687 | - | - | Stock Option (Right to Buy) | ||
| Phathom Pharmaceuticals Inc | Terrie Curran | Director, President and Chief Executive | 22 Mar 2021 | 10,373 | 1,140 (0%) | 0% | 43.2 | 448,495 | Common Stock | |
| Phathom Pharmaceuticals Inc | Terrie Curran | Director, President and Chief Executive | 22 Mar 2021 | 1,140 | 0 (0%) | 0% | 44.1 | 50,256 | Common Stock | |
| Phathom Pharmaceuticals Inc | Terrie Curran | Director, President and Chief Executive | 28 Jan 2021 | 225,000 | 225,000 | - | - | Stock Option (Right to Buy) | ||
| Arcutis Biotherapeutics Inc | Terrie Curran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Nov 2020 | 37,500 | 37,500 | - | - | Stock Option (Right to Buy) |